What Johnson & Johnson and Eli Lilly are saying about Trump’s pharmaceutical tariffs, and Dexcom scores FDA approval for its ...

In this week’s edition of InnovationRx, we look at the impact of Medicaid cuts, a $400 million obesity bet, a study of bias ...

U.S. tariffs on pharmaceuticals could eventually mean higher prices for brand-name medicines, but in the near term the costs ...

Pharma companies are leveraging the United States’ threat of tariffs on drug imports to push for policy changes in the EU. | Pharma companies are leveraging the Trump administration’s threat of ...

European regulators have finally approved the Alzheimer’s treatment Leqembi after an advisory committee initially rejected the drug last summer.

Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.

Levies on Americans’ daily prescriptions and other medicines could raise costs, spur rationing and lead to shortages of ...

Jim Cramer recently highlighted Eli Lilly and Company (LLY) as a standout example of corporate efficiency, praising its ability to build a factory in record time. The factory, located in Concord, ...

For adults struggling with weight, a weekly injection of tirzepatide offers real hope. Recent findings presented at the ...

The stock of U.S. pharmaceutical giant Eli Lilly (LLY) is up 3% on news that rival Pfizer (PFE) has ended development of its experimental ...

Pfizer on Monday announced it is halting development of a daily weight loss pill after one patient experienced a liver injury ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...